ストックスクリーナーアプリを入手
47.19
6.18%
-3.11
アフターアワーズ：
47.70
0.51
+1.08%
前日終値:
$50.30
開ける：
$47.95
24時間の取引高:
46.59M
Relative Volume:
2.20
時価総額：
$209.69B
収益：
$46.69B
当期純損益:
$15.29B
株価収益率:
13.75
EPS:
3.4329
ネットキャッシュフロー:
$9.25B
1週間 パフォーマンス:
-21.78%
1か月 パフォーマンス:
-9.93%
6か月 パフォーマンス:
-3.32%
1年 パフォーマンス:
-42.88%
1日の値動き範囲:
$46.47
$49.10
1週間の範囲:
$46.47
$59.93
52週間の値動き範囲:
$43.08
$93.80
Novo Nordisk Adr Stock (NVO) Company Profile
NVO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
47.19 | 223.51B | 46.69B | 15.29B | 9.25B | 3.4329 |
|
LLY
Lilly Eli Co
|
1,107.12 | 898.12B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
234.47 | 561.61B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
217.11 | 398.83B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
MRK
Merck Co Inc
|
118.33 | 287.52B | 65.00B | 18.26B | 13.05B | 7.2751 |
|
NVS
Novartis Ag Adr
|
152.91 | 287.55B | 54.45B | 14.42B | 17.15B | 7.333 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-27 | 開始されました | Citigroup | Neutral |
| 2025-12-08 | ダウングレード | Argus | Buy → Hold |
| 2025-10-27 | 再開されました | Jefferies | Underperform |
| 2025-10-01 | アップグレード | HSBC Securities | Hold → Buy |
| 2025-09-29 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2025-09-17 | アップグレード | Berenberg | Hold → Buy |
| 2025-09-16 | アップグレード | Rothschild & Co Redburn | Neutral → Buy |
| 2025-09-09 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2025-08-13 | アップグレード | BNP Paribas Exane | Underperform → Neutral |
| 2025-08-05 | ダウングレード | UBS | Buy → Neutral |
| 2025-07-31 | ダウングレード | HSBC Securities | Buy → Hold |
| 2025-07-30 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2025-04-17 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2025-03-13 | アップグレード | Kepler | Hold → Buy |
| 2025-03-03 | ダウングレード | Stifel | Buy → Hold |
| 2025-02-12 | 開始されました | Morgan Stanley | Equal-Weight |
| 2025-01-06 | アップグレード | Bernstein | Underperform → Mkt Perform |
| 2024-05-30 | 開始されました | Goldman | Buy |
| 2024-04-12 | 開始されました | BMO Capital Markets | Outperform |
| 2024-01-23 | 開始されました | Morgan Stanley | Overweight |
| 2024-01-16 | 再開されました | UBS | Neutral |
| 2023-12-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-10-02 | 開始されました | Argus | Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2022-07-15 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-06-28 | ダウングレード | UBS | Neutral → Sell |
| 2022-06-27 | アップグレード | Exane BNP Paribas | Underperform → Neutral |
| 2022-06-07 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-05-31 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-04-25 | アップグレード | Cowen | Market Perform → Outperform |
| 2022-04-12 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2022-03-16 | アップグレード | Deutsche Bank | Hold → Buy |
| 2022-01-25 | ダウングレード | Liberum | Hold → Sell |
| 2021-12-20 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-12-17 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2021-01-20 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2021-01-15 | 開始されました | Deutsche Bank | Buy |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-07-06 | ダウングレード | BofA Securities | Buy → Neutral |
| 2020-05-11 | ダウングレード | UBS | Buy → Neutral |
| 2020-05-04 | 開始されました | Cowen | Market Perform |
| 2020-03-16 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2020-01-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-11-18 | アップグレード | Barclays | Equal Weight → Overweight |
| 2019-09-17 | アップグレード | Citigroup | Neutral → Buy |
| 2019-08-30 | ダウングレード | Jefferies | Hold → Underperform |
| 2019-06-20 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2019-06-11 | アップグレード | Barclays | Underweight → Equal Weight |
| 2019-04-29 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2019-01-29 | 開始されました | Exane BNP Paribas | Outperform |
| 2018-12-11 | 再開されました | Jefferies | Hold |
| 2018-10-09 | 開始されました | Guggenheim | Buy |
| 2017-12-29 | アップグレード | JP Morgan | Underweight → Neutral |
| 2017-12-06 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2017-12-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2017-09-25 | ダウングレード | Exane BNP Paribas | Outperform → Neutral |
| 2017-09-06 | アップグレード | BofA/Merrill | Underperform → Neutral |
すべてを表示
Novo Nordisk Adr (NVO) 最新ニュース
Novo Nordisk Faces a Reality Check as Pricing Pressure Hits 2026 Forecasts - Investing.com
NVO Q4 Earnings & Sales Beat Estimates, Stock Down on Poor 2026 View - Finviz
Novo Nordisk ADR earnings beat by $0.10, revenue topped estimates - Investing.com Australia
Novo Nordisk's U.S. listing drops significantly after earnings report - medwatch.com
Jim Cramer Believes Novo Nordisk "Is a Hold, Not a Buy" - Finviz
Is Novo Nordisk Stock a Bargain Right Now? - Finviz
BMO Raises Novo Nordisk A/S (NVO) Price Target but Flags Prescription Pressures - Finviz
Should You Buy Novo Nordisk Stock on Oral Wegovy's Strong Launch? - Finviz
Demand for Novo Nordisk's Weight Loss Pill Is Strong Out of the Gate. Is the Stock Due for a Big Rally? - Finviz
Novo Nordisk Before Q4 Earnings: How Should Investors Play the Stock? - Finviz
5 Stocks To Keep an Eye On in 2026, According to Experts - AOL.com
Novo Nordisk’s Wegovy Pill And Akero Deal Reframe Obesity Growth Story - Sahm
Market Trends: What is the next catalyst for ISPCRate Cut & Weekly Setup with ROI Potential - baoquankhu1.vn
Stock Report: Is Novo Nordisk A s b Shares Adrhedged in a consolidation phaseJuly 2025 Highlights & Real-Time Sentiment Analysis - baoquankhu1.vn
Novo Nordisk AS (NVO) Stock Price, Trades & News - GuruFocus
Jim Cramer on Novo Nordisk: "I Think They're Making a Turn Here" - Finviz
Novo Nordisk ADR: Weight?loss Champion Faces High?Altitude Turbulence - AD HOC NEWS
Novo Nordisk Deepens Cell Therapy Push In Canada As Shares Screen Cheap - Sahm
Key facts: Novo Nordisk stock rises 9.12%; expands diabetes partnership; launches Ozempic ad campaign - TradingView
Is Oral Wegovy a Game Changer for Novo Nordisk? - Finviz
Novo Nordisk A/S-Spons ADR (NYSE:NVO) Demonstrates a Strong Dividend Profile Backed by High Profitability - Chartmill
Shorts Report: Can Novo Nordisk A s b Shares Adrhedged be the next market leader - baoquankhu1.vn
Eli Lilly vs. Novo Nordisk: Which Is the Better Stock Buy? - Finviz
Novo Nordisk (NVO) is "in a Battle," Says Jim Cramer - Finviz
Europe’s ADR Index Was Flat, But Single Stocks Were Not - Finimize
Eli Lilly vs Novo Nordisk: Which Company Will Dominate the Weight Loss Drug Market in 2026? - Finviz
Can Novo Nordisk Unseat Eli Lilly as the Weight Loss Drug Leader in 2026? - Finviz
Looking At Novo Nordisk's Recent Unusual Options Activity - Sahm
Can Novo Nordisk A s (b Shares) Adrhedged stock continue upward trendWeekly Loss Report & Daily Risk Controlled Trade Plans - Улправда
Novo Nordisk gets a fresh $73.50 target as Amazon starts selling the Wegovy pill - TechStock²
CICC Initiates Coverage on Novo Nordisk with Outperform Rating and $73.50 Price Target for U.S. ADRBN - marketscreener.com
Novo Nordisk A/S (B Shares) ADRhedged (BATS:NVOH) Trading 0.4% Higher – What’s Next? - Defense World
Novo Nordisk Adr (NVO) 財務データ
収益
当期純利益
現金流量
EPS
8.15%
大文字化:
|
ボリューム (24 時間):